Developments in small molecule immunosuppressive drugs

Ying Liu, Yu Bin Wang, Qi Zhang, Jin-Xiong She

Research output: Contribution to journalReview article

Abstract

Most of the immunosuppressive agents used in clinic are developed from microbial secondary metabolites, such as tacrolimus, cyclosporine and so on. They have satisfactory therapeutic effects on organ transplantation and autoimmune diseases, but their clinical application is limited by their side effects. In recent years, a lot of novel small molecule immunosuppressants with higher activity and milder side effects have been developed. In this paper, small molecule immunosuppressive drugs were classified according to their targets and the mechanisms, and the development status and adverse reactions of some novel immunosuppressive drugs were reviewed. These drugs include sphingosine-1-phosphate (S1P) agonists, and the inhibitors of dihydroorotate dehydrogenase (DHODH), protein kinase C (PKC) and Janus kinase 3 (JAK3).

Original languageEnglish (US)
Pages (from-to)1981-1988
Number of pages8
JournalChinese Journal of New Drugs
Volume20
Issue number20
StatePublished - Oct 30 2011

Fingerprint

Immunosuppressive Agents
Pharmaceutical Preparations
Janus Kinase 3
Tacrolimus
Organ Transplantation
Therapeutic Uses
Cyclosporine
Autoimmune Diseases

Keywords

  • Dihydroorotate dehydrogenase
  • Immunosuppressant
  • Janus kinase 3
  • Protein kinase C
  • Sphingosine-1-phosphate

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)

Cite this

Developments in small molecule immunosuppressive drugs. / Liu, Ying; Wang, Yu Bin; Zhang, Qi; She, Jin-Xiong.

In: Chinese Journal of New Drugs, Vol. 20, No. 20, 30.10.2011, p. 1981-1988.

Research output: Contribution to journalReview article

Liu, Y, Wang, YB, Zhang, Q & She, J-X 2011, 'Developments in small molecule immunosuppressive drugs', Chinese Journal of New Drugs, vol. 20, no. 20, pp. 1981-1988.
Liu, Ying ; Wang, Yu Bin ; Zhang, Qi ; She, Jin-Xiong. / Developments in small molecule immunosuppressive drugs. In: Chinese Journal of New Drugs. 2011 ; Vol. 20, No. 20. pp. 1981-1988.
@article{04b948281fa74003a96fa6529e9212a3,
title = "Developments in small molecule immunosuppressive drugs",
abstract = "Most of the immunosuppressive agents used in clinic are developed from microbial secondary metabolites, such as tacrolimus, cyclosporine and so on. They have satisfactory therapeutic effects on organ transplantation and autoimmune diseases, but their clinical application is limited by their side effects. In recent years, a lot of novel small molecule immunosuppressants with higher activity and milder side effects have been developed. In this paper, small molecule immunosuppressive drugs were classified according to their targets and the mechanisms, and the development status and adverse reactions of some novel immunosuppressive drugs were reviewed. These drugs include sphingosine-1-phosphate (S1P) agonists, and the inhibitors of dihydroorotate dehydrogenase (DHODH), protein kinase C (PKC) and Janus kinase 3 (JAK3).",
keywords = "Dihydroorotate dehydrogenase, Immunosuppressant, Janus kinase 3, Protein kinase C, Sphingosine-1-phosphate",
author = "Ying Liu and Wang, {Yu Bin} and Qi Zhang and Jin-Xiong She",
year = "2011",
month = "10",
day = "30",
language = "English (US)",
volume = "20",
pages = "1981--1988",
journal = "Chinese Journal of New Drugs",
issn = "1003-3734",
publisher = "Chinese Journal of New Drugs Co. Ltd.",
number = "20",

}

TY - JOUR

T1 - Developments in small molecule immunosuppressive drugs

AU - Liu, Ying

AU - Wang, Yu Bin

AU - Zhang, Qi

AU - She, Jin-Xiong

PY - 2011/10/30

Y1 - 2011/10/30

N2 - Most of the immunosuppressive agents used in clinic are developed from microbial secondary metabolites, such as tacrolimus, cyclosporine and so on. They have satisfactory therapeutic effects on organ transplantation and autoimmune diseases, but their clinical application is limited by their side effects. In recent years, a lot of novel small molecule immunosuppressants with higher activity and milder side effects have been developed. In this paper, small molecule immunosuppressive drugs were classified according to their targets and the mechanisms, and the development status and adverse reactions of some novel immunosuppressive drugs were reviewed. These drugs include sphingosine-1-phosphate (S1P) agonists, and the inhibitors of dihydroorotate dehydrogenase (DHODH), protein kinase C (PKC) and Janus kinase 3 (JAK3).

AB - Most of the immunosuppressive agents used in clinic are developed from microbial secondary metabolites, such as tacrolimus, cyclosporine and so on. They have satisfactory therapeutic effects on organ transplantation and autoimmune diseases, but their clinical application is limited by their side effects. In recent years, a lot of novel small molecule immunosuppressants with higher activity and milder side effects have been developed. In this paper, small molecule immunosuppressive drugs were classified according to their targets and the mechanisms, and the development status and adverse reactions of some novel immunosuppressive drugs were reviewed. These drugs include sphingosine-1-phosphate (S1P) agonists, and the inhibitors of dihydroorotate dehydrogenase (DHODH), protein kinase C (PKC) and Janus kinase 3 (JAK3).

KW - Dihydroorotate dehydrogenase

KW - Immunosuppressant

KW - Janus kinase 3

KW - Protein kinase C

KW - Sphingosine-1-phosphate

UR - http://www.scopus.com/inward/record.url?scp=84859482242&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859482242&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:84859482242

VL - 20

SP - 1981

EP - 1988

JO - Chinese Journal of New Drugs

JF - Chinese Journal of New Drugs

SN - 1003-3734

IS - 20

ER -